Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. The Lancet Neurology. Volume 19. Lancet Publishing Group; 2020. pp. 951–62.
Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer’s disease. Neuroimage Clin. 2018;19:625–32.
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71(4):266–73.
Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, et al. Prevalence and clinical phenotype of Quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77(10):1299–307.
Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer’s disease. Brain. 2021;144(3):953–62.
Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–12.
Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021;144(7):2186–98.
Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, Vöglein J, et al. α-Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer’s disease late in the disease course and dependent on Lewy pathology burden. Alzheimer’s & Dementia. 2024;20(6):4351–4365.
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313(19):1939.
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med. 2014;6(226):226ra30.
Jack CR, Holtzman DM. Biomarker modeling of alzheimer’s disease. Volume 80. Neuron. Cell; 2013. pp. 1347–58.
Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer. Nat Commun. 2022;13(1):6635.
Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease. Sci Adv. 2020;6(16):eaaz2387.
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–49.
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188.
Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain. 2023;146(4):1580–91.
Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging. 2009;30(12):1895–901.
Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p‐tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.
Rabinovici GD, Knopman D, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O et al. Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease: Alzheimer’s Association Workgroup. [cited 2024 May 2]; https://aaic.alz.org/diagnostic-criteria.asp
Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77(7):829.
Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561–71.
Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477–94.
Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, et al. Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease. Brain. 2021;144(8):2284–90.
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016;4(1).
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA – J Am Med Association. 2018;320(11):1151–62.
Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230–42.
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818–2830.
Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 Tau Positron Emission Tomography in the differentiation of Alzheimer Disease from Other Neurodegenerative disorders. JAMA Neurol. 2020;77(8):955–65.
Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021;48(7):2295–305.
Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.
Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110–9.
Macedo AC, Therriault J, Tissot C, Fernandez-Arias J, Ferreira PCL, Vitali P et al. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging. Brain Commun. 2024;6(2).
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2021;7(1).
Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601–12.
La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer Disease with the pattern of tau- and Amyloid-PET. Neurology. 2021;96(5):e650–61.
Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. The Lancet Neurology. Volume 21. Elsevier Ltd; 2022. pp. 726–34.
Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097–109.
De Wilde A, Van Der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062–70.
Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FRJ, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2.
Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, Van Der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer’s Dement. 2013;9(4):414–21.
Shekari M, Verwer EE, Yaqub M, Daamen M, Buckley C, Frisoni GB, et al. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan. EJNMMI Phys. 2023;10(1):68.
Coomans EM, de Koning LA, Rikken RM, Verfaillie SCJ, Visser D, den Braber A et al. Performance of a [ 18 F]flortaucipir PET visual read Method across the Alzheimer Disease Continuum and in Dementia with Lewy Bodies. Neurology. 2023;101(19).
van der Bij AK, de Weerd S, Cikot RJLM, Steegers EAP, Braspenning JCC. Validation of the Dutch short form of the State Scale of the Spielberger state-trait anxiety inventory: considerations for usage in screening outcomes. Public Health Genomics. 2003;6(2):84–7.
Marteau TM, Bekker H. The development of a six-item short‐form of the state scale of the Spielberger State—trait anxiety inventory (STAI). Br J Clin Psychol. 1992;31(3):301–6.
Mishel MH, Braden CJ. Finding meaning: antecedents of uncertainty in illness. Nurs Res. 1988;37(2):98–103.
Nyman SR, Casey C, Polman R. Psychometric properties of the ICECAP-O Quality of Life Measurement Tool when Self-reported by community-dwelling older people with mild and moderate dementia. Alzheimer Dis Assoc Disord. 2021;35(4):356–9.
Arraras JI, Greimel E, Sezer O, Chie WC, Bergenmar M, Costantini A, et al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer. 2010;46(15):2726–38.
Brehaut JC, O’Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Mak. 2003;23(4):281–92.
Altomare D, Caprioglio C, Assal F, Allali G, Mendes A, Ribaldi F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021;48:2200–2211.
Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, et al. Clinical effect of early vs late amyloid Positron Emission Tomography in Memory Clinic patients: the AMYPAD-DPMS Randomized Clinical Trial. JAMA Neurol. 2023;80(6):548–57.
Smith R, Hägerström D, Pawlik D, Klein G, Jögi J, Ohlsson T, et al. Clinical utility of tau Positron Emission Tomography in the diagnostic workup of patients with cognitive symptoms. JAMA Neurol. 2023;1;80(7):749–756.
Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography with subsequent change in Clinical Management among Medicare Beneficiaries with mild cognitive impairment or dementia. JAMA – J Am Med Association. 2019;321(13):1286–94.
van Maurik IS, Broulikova HM, Mank A, Bakker ED, de Wilde A, Bouwman FH, et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimer’s Dement. 2023;19(5):2006–13.
Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology. 2023;100(3).
Josephs KA, Tosakulwong N, Weigand SD, Graff-Radford J, Schwarz CG, Senjem ML et al. Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease. Sci Transl Med. 2024;16(757).
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, et al. The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48(7):2070–85.
Rabinovici GD, Knopman D, Arbizu J, Donohoe STL, Hansson KJ. O, 2024 AUC for amyloid and tau PET: updated appropriate use criteria for amyloid and tau PET in Alzheimer’s Disease. Butler Hospital Memory and Aging Program. 2024;17.
Add Comment